See more : Postal Savings Bank of China Co., Ltd. (1658.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Axonics, Inc. (AXNX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Axonics, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- PT Suryamas Dutamakmur Tbk (SMDM.JK) Income Statement Analysis – Financial Results
- Merus N.V. (MRUS) Income Statement Analysis – Financial Results
- Arabian Shield Cooperative Insurance Company (8070.SR) Income Statement Analysis – Financial Results
- Edison Opto Corporation (3591.TW) Income Statement Analysis – Financial Results
- good natured Products Inc. (GDNP.V) Income Statement Analysis – Financial Results
Axonics, Inc. (AXNX)
About Axonics, Inc.
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 366.38M | 273.70M | 180.29M | 111.54M | 13.82M | 707.00K | 128.12K | 0.00 |
| Cost of Revenue | 91.83M | 76.04M | 64.57M | 44.44M | 6.49M | 356.00K | 117.94K | 625.12K |
| Gross Profit | 274.55M | 197.67M | 115.72M | 67.09M | 7.33M | 351.00K | 10.17K | -625.12K |
| Gross Profit Ratio | 74.94% | 72.22% | 64.18% | 60.15% | 53.04% | 49.65% | 7.94% | 0.00% |
| Research & Development | 34.89M | 34.41M | 37.30M | 29.17M | 20.18M | 19.40M | 12.33M | 12.51M |
| General & Administrative | 45.75M | 40.24M | 32.79M | 25.55M | 19.08M | 9.36M | 4.82M | 4.46M |
| Selling & Marketing | 189.56M | 156.02M | 105.79M | 66.13M | 48.67M | 3.72M | 1.03M | 516.08K |
| SG&A | 235.32M | 196.26M | 138.57M | 91.68M | 67.75M | 13.09M | 5.85M | 4.97M |
| Other Expenses | 14.96M | 9.38M | 7.24M | -412.15K | 0.00 | 0.00 | -20.82K | -291.00 |
| Operating Expenses | 270.20M | 240.05M | 183.11M | 120.85M | 87.93M | 32.49M | 18.19M | 17.48M |
| Cost & Expenses | 392.44M | 316.09M | 247.68M | 165.30M | 94.42M | 32.84M | 18.30M | 17.48M |
| Interest Income | 17.31M | 5.13M | 40.00K | 761.00K | 2.97M | 998.00K | 200.58K | 84.02K |
| Interest Expense | 0.00 | 2.43M | 7.43M | 1.87M | 2.31M | 1.34M | 22.00K | 0.00 |
| Depreciation & Amortization | 12.49M | 12.72M | 10.13M | 2.64M | 1.59M | 946.00K | 725.39K | 625.12K |
| EBITDA | 7.78M | -47.16M | -61.73M | -51.30M | -78.03M | -31.19M | -17.33M | -16.77M |
| EBITDA Ratio | 2.12% | -10.18% | -33.34% | -47.52% | -561.69% | -4,404.38% | -13,479.81% | 0.00% |
| Operating Income | -26.06M | -42.39M | -67.39M | -53.76M | -80.60M | -32.14M | -18.17M | -17.48M |
| Operating Income Ratio | -7.11% | -15.49% | -37.38% | -48.20% | -583.21% | -4,545.54% | -14,185.62% | 0.00% |
| Total Other Income/Expenses | 17.31M | 2.63M | -7.48M | -1.15M | 665.00K | -345.00K | 114.33K | 82.93K |
| Income Before Tax | -8.74M | -62.32M | -79.29M | -54.91M | -79.93M | -32.48M | -18.06M | -17.40M |
| Income Before Tax Ratio | -2.39% | -22.77% | -43.98% | -49.23% | -578.39% | -4,594.34% | -14,097.05% | 0.00% |
| Income Tax Expense | -2.66M | -2.62M | 782.00K | 1.00K | 1.00K | 1.00K | -20.82K | -291.00 |
| Net Income | -6.09M | -59.70M | -80.07M | -54.92M | -79.94M | -32.48M | -18.06M | -17.40M |
| Net Income Ratio | -1.66% | -21.81% | -44.41% | -49.24% | -578.40% | -4,594.48% | -14,097.05% | 0.00% |
| EPS | -0.12 | -1.28 | -1.86 | -1.48 | -2.80 | -4.64 | -0.97 | -0.95 |
| EPS Diluted | -0.12 | -1.28 | -1.86 | -1.48 | -2.80 | -4.64 | -0.97 | -0.95 |
| Weighted Avg Shares Out | 49.08M | 46.68M | 43.07M | 36.98M | 28.57M | 7.00M | 18.62M | 18.38M |
| Weighted Avg Shares Out (Dil) | 49.08M | 46.68M | 43.07M | 36.98M | 28.57M | 7.00M | 18.62M | 18.38M |
3 Stocks Backed by High Efficiency to Increase Portfolio Returns
Wall Street Analysts Believe Axonics (AXNX) Could Rally 25.1%: Here's is How to Trade
Axonics to Participate in November Investor Conferences
New Strong Buy Stocks for October 31st
Axonics, Inc. (AXNX) Q3 2023 Earnings Call Transcript
Axonics Modulation Technologies (AXNX) Q3 Earnings and Revenues Top Estimates
Axonics Reports Third Quarter 2023 Financial Results
5 Top Stocks Set to Beat Q3 Earnings Estimates on Monday
Axonics Modulation Technologies (AXNX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Axonics to Report Third Quarter 2023 Financial Results on October 30
Source: https://incomestatements.info
Category: Stock Reports